Asia Pacific Blood-based Biomaker For Sports Medicine Market Size & Outlook
Asia Pacific blood-based biomaker for sports medicine market, 2018-2030 (US$M)
Related Markets
Asia Pacific blood-based biomaker for sports medicine market highlights
- The Asia Pacific blood-based biomaker for sports medicine market generated a revenue of USD 144.5 million in 2023.
- The market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, ck was the largest revenue generating type in 2023.
- CRP is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 144.5 million |
| Market revenue in 2030 | USD 259.9 million |
| Growth rate | 8.7% (CAGR from 2023 to 2030) |
| Largest segment | Ck |
| Fastest growing segment | CRP |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CK, Myoglobin, Lactate, WBC, Urea, CRP, Lipid and Protein Hydroperoxides, IL-6 |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 21.7% of the global blood-based biomaker for sports medicine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 259.9 million by 2030.
Ck was the largest segment with a revenue share of 18.13% in 2023. Horizon Databook has segmented the Asia Pacific blood-based biomaker for sports medicine market based on ck, myoglobin, lactate, wbc, urea, crp, lipid and protein hydroperoxides, il-6 covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific region is expected to witness significant growth for the blood-based biomarker for sports medicine market, driven by increasing investment in R&D. This surge is fueled by the rising awareness of the importance of personalized athlete health management and the need for advanced injury prevention & performance optimization.
Partnerships and collaborations among these companies, research institutions, and sports organizations are enhancing the development & adoption of cuttingedge biomarker solutions. For instance, in October 2023, Fujirebio Holdings, Inc. and Sysmex Corporation announced a Basic Agreement on Business Collaboration.
This agreement aims to enhance their multifaceted partnership, focusing on R&D, production, clinical development, and sales & marketing. These strategic alliances facilitate the sharing of expertise and resources, accelerating advancements in sports medicine and improving athlete health management across Asia Pacific.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood-based Biomaker for Sports Medicine Market Scope
Blood-based Biomaker for Sports Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific blood-based biomaker for sports medicine market size, by country, 2018-2030 (US$M)
Asia Pacific Blood-based Biomaker for Sports Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
